Division of Infectious Diseases and Hospital Epidemiology
Basel, 4031, Switzerland
Location status: Recruiting
Location contact
Isabelle Vock, Dipl. med.
SUB_INVESTIGATOR
Sarah Tschudin Sutter, PD MD
CONTACT
NCT Number: NCT04098133
This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Basel, 4031, Switzerland
Location status: Recruiting
Isabelle Vock, Dipl. med.
SUB_INVESTIGATOR
Sarah Tschudin Sutter, PD MD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
Time frame: from January 1st , 2008 until December 31st, 2028
incidence of CPB at the University Hospital Basel (number)
Time frame: from January 1st , 2008 until December 31st, 2028
time to detection of CPB (days)
Time frame: from January 1st , 2008 until December 31st, 2028
time to initiation of infection control measures
Time frame: from January 1st , 2008 until December 31st, 2028
time to adequate treatment in patients with CPB infections
Time frame: from January 1st , 2008 until December 31st, 2028
presence of established risk factors for CPB
Time frame: from January 1st , 2008 until December 31st, 2028
length of hospital stay (days)
Time frame: from January 1st , 2008 until December 31st, 2028
discharge destination
Time frame: from January 1st , 2008 until December 31st, 2028
cure from infection
Time frame: from January 1st , 2008 until December 31st, 2028
cause-specific mortality (number)
Time frame: from January 1st , 2008 until December 31st, 2028
all-cause mortality (number)
Contact information is provided by the study sponsor or research team.
Isabelle Vock, Dipl. med
CONTACT
Sarah Tschudin Sutter, Prof. Dr. MD
CONTACT
University Hospital, Basel, Switzerland
Other
Acronym: CPB-Epi Basel
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.